{"filings":[{"id":2022036,"accession_number":"0001437749-26-025423","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2026-08-03T19:12:22+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative Technology borrows $400K from CEO via two bridge notes at 8% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On May 8 and July 16, 2026, company issued bridge notes totaling $400,000 to CEO Junli He.","Each note bears 8% fixed interest, matures on earlier of $5M capital raise or one year.","Notes are convertible into equity at lender's option upon a qualified financing of at least $200,000.","Transaction approved by disinterested board members; constitutes related party transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2021836,"accession_number":"0001437749-26-025419","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K/A","filed_at":"2026-08-03T19:07:44+00:00","items":["1.02","1.01","2.03","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative Technology amends 8-K; discloses $300K bridge note from CEO","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment corrects prior 8-K: loan from CEO Junli He was a new agreement, not a termination.","Bridge Note: $300,000 principal, 8% fixed interest, due April 13, 2027 or upon $5M capital raise.","Optional conversion at lender's discretion; includes customary covenants and events of default.","Loan provided by Chairman and CEO Junli He."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1230882,"accession_number":"0001437749-26-021480","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2026-06-23T23:49:47+00:00","items":["5.07"],"status":"ready","headline":"Annual meeting results: all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Junli (Jerry) He elected with 12.8M votes for, 0.86M withheld; James Shmerling with 10.7M for, 2.9M withheld; Mao Zhang with 12.8M for, 0.86M withheld.","Ratification of CBIZ CPAs P.C. as auditor for FY2026 approved with 14.1M for, 5,417 against, 853K abstain.","Non-binding advisory vote on executive compensation approved with 12.5M for, 39K against, 1.2M abstain, 1.3M broker non-votes.","All proposals passed with required votes; no material changes to board composition or governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93674,"accession_number":"0001437749-26-013677","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative Technology treats first patient in Phase 1 esophageal implant trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient treated with Cellspan Esophageal Implant (CEI) in Phase 1 clinical trial at Mayo Clinic.","Phase 1 trial is a feasibility and safety study in up to 10 patients under an FDA-approved IND, with three active clinical sites.","Primary endpoint: establishment of a continuous biological neoconduit by three months post-surgery; secondary: mucosal lining by 12 months.","CEI combines a polyurethane scaffold with autologous adipose-derived mesenchymal stromal cells; scaffold removed endoscopically at 21-42 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93673,"accession_number":"0001437749-26-012380","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Harvard Apparatus receives $300K bridge loan from CEO Junli He at 8% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan of $300,000 from Chairman/CEO Junli He; annual 8% fixed interest rate.","Matures on earlier of closing of $5M+ capital raise or April 13, 2027.","Lender may optionally convert principal and accrued interest into equity at next qualified financing.","Related-party transaction filed under Item 1.02; note contains customary events of default.","Company trades on OTCQB under ticker HRGN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105492,"accession_number":"0001437749-26-000452","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative Technology raises ~$0.7M in private placement of 411,765 shares at $1.70/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 411,765 shares of common stock at $1.70 per share for aggregate proceeds of approximately $0.7 million.","Private placement exempt under Section 4(a)(2) and Rule 506; securities not registered.","Purchase agreements effective December 30, 2025; no use of proceeds disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138440,"accession_number":"0001437749-25-022650","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Harvard Apparatus raises $2.0M via private placement of 1.25M shares at $1.60/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,250,000 shares of common stock to accredited investors for aggregate proceeds of ~$2.0M.","Per-share purchase price of $1.60; closing occurred on July 11, 2025.","Shares issued in reliance on Section 4(a)(2) and Rule 506 exemption from registration.","Customary representations, warranties and covenants in the Securities Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155902,"accession_number":"0001437749-25-021097","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Harvard Apparatus shareholders approve reverse stock split and declassification amendment at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split amendment approved; Board authorized to determine ratio and timing at discretion.","Declassification amendment eliminates staggered board; special meetings can be called by holders of at least 35% voting power.","Directors Jason Chen and Herman Sanchez elected as Class III directors with 12.7M and 8.3M votes for, respectively.","Ratification of CBIZ CPAs as auditor for FY2025 passed with 14.4M for, 28K against; say-on-pay advisory vote passed.","All proposals passed with strong shareholder support; broker non-votes reported for most items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155901,"accession_number":"0001437749-25-011884","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative Tech replaces auditor: Marcum resigns, CBIZ CPAs P.C appointed April 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor effective April 11, 2025; Audit Committee approved CBIZ CPAs P.C. as successor the same day.","No disagreements with Marcum on accounting principles, disclosure, or audit scope during fiscal 2023, 2024, or through April 14, 2025.","Marcum's reports for fiscal 2023 and 2024 were unqualified but included a going-concern explanatory paragraph.","Marcum's letter concurring with disclosure is filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191307,"accession_number":"0001493152-24-043862","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative Technology signs exclusive global distribution deal with Health Regen through 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive distribution of consumer health/dietary supplements from Nov 1, 2024 to Dec 31, 2030; auto-renews for 6 years if targets met.","Annual sales targets: $1M (2025) escalating to $20M (2030); Company receives 10% markup on manufacturing costs plus pass-through costs.","Early termination by Company triggers penalty of 3x projected annual sales in year 6.","Chinese subsidiary employees and inventory to be transferred to Health Regen effective Nov 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207789,"accession_number":"0001493152-24-034014","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative Technology appoints StellarS Capital CEO Mao Zhang to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mao Zhang, Founder & CEO of multi-billion-dollar alternative asset manager StellarS Capital, appointed as independent Class I director effective Aug 26, 2024.","Mr. Zhang will receive $25,000 stock option grant vesting quarterly over one year; standard non-employee director compensation ($20k cash + $25k options annually).","Mr. Zhang has over 15 years financial markets experience; previously led Magnetar Capital's Asian business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207788,"accession_number":"0001493152-24-033401","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Harvard Apparatus raises $5.0M via private placement of 1.39M shares at $3.60/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,388,888 shares to Stellars Capital at $3.60/share for approx $5.0 million.","Company must add one board member designated by investor and seek declassification of board and allow special meetings by 35% holders.","Shares issued in unregistered private placement under Section 4(a)(2) and Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225266,"accession_number":"0001493152-24-024931","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders elect three directors, ratify auditor, and approve executive compensation at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Green, Ting Li, and Ronald Packard elected as Class II directors for three-year terms.","Ratification of Marcum LLP as independent auditor for FY 2024 passed with 9,738,743 votes for.","Non-binding advisory approval of named executive officer compensation passed with 8,033,183 votes for.","Broker non-votes on director election totaled 1,695,472 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225265,"accession_number":"0001493152-24-015052","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative Technology raises $1.5M in private placement of 367,767 shares at $4.03/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate purchase price of $1.5 million for 367,767 shares at $4.03 per share in a private placement.","Shares sold exempt from registration under Section 4(a)(2) and Rule 506 of the Securities Act.","Shares to be fully paid, non-assessable, and free of liens upon issuance.","Securities Purchase Agreement includes customary representations, warranties, and covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244469,"accession_number":"0001493152-24-005102","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative Technology enters $500K bridge note with CEO Junli He at 8% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Bridge note for $500,000 from Chairman/CEO Junli He; 8% annual interest on 360-day basis.","Maturity on earlier of next capital raise >= $5M gross proceeds or Feb 1, 2025.","Lender has optional conversion to equity in any Qualified Financing of $500K+ (excluding this note).","Prepayment permitted without penalty; events of default include bankruptcy, non-payment, breach of covenants.","Proceeds provide near-term working capital; insider loan aligns interests but adds related-party exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279090,"accession_number":"0001493152-23-025017","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Harvard Apparatus Regenerative (fka Biostage) trades under HRGN; FDA clears 10-patient phase 1 esophageal study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed from Biostage to Harvard Apparatus Regenerative Technology; new ticker HRGN on OTCQB effective July 20, 2023.","FDA approved a 10-patient phase 1 study for esophageal implant; enrollment opened.","Company plans to launch anti-aging business in China; expects it to be cash flow positive in fiscal 2023.","Launched new website www.hregen.com to highlight regenerative technology and anti-aging strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279089,"accession_number":"0001493152-23-024951","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biostage annual meeting: all four proposals pass, equity plan amended","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Junli He and James Shmerling elected as Class I directors; He received 10,377,115 'for' votes, Shmerling 2,345,415 'for' with 8,041,390 withheld.","Ratification of Marcum LLP as auditor for FY2023 approved: 11,763,540 for, 5,174 against, 473 abstentions.","Amendment to Amended and Restated Equity Incentive Plan to increase share reserve by 4,000,000 shares approved: 10,370,321 for, 16,358 against, 126 abstentions.","Non-binding advisory vote on executive compensation approved: 10,184,823 for, 12,603 against, 189,379 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279088,"accession_number":"0001493152-23-024106","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K/A","filed_at":"2023-07-10T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Biostage reduces CEO milestone stock options from 488,256 to 267,616 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment corrects Milestone Grant for CEO Junli He from 488,256 to 267,616 shares.","Each vesting increment reduced from 244,128 to 133,808 shares, still two tranches.","Effective retroactively to March 14, 2023; no other changes to employment agreement.","Reduction lowers potential dilution from milestone options by approximately 45%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297421,"accession_number":"0001493152-23-011655","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Biostage appoints Ron Packard, CEO of Pansophic Learning, to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ron Packard appointed as Class II director effective April 5, 2023; term until 2024 annual meeting.","Receives stock options valued at $25,000 vesting quarterly over one year; also standard non-employee director compensation ($20,000 cash + $25,000 annual option grant).","Packard is CEO/Founder of Pansophic Learning, former CEO/Founder of K12 Inc., which he grew to ~$1B revenue and led through NYSE IPO.","Previous roles include McKinsey & Company (biotech/semiconductors), Goldman Sachs (M&A), and holds CFA designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297420,"accession_number":"0001493152-23-011145","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2023-04-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Biostage raises ~$6M via private placement of 1M shares at $6.00; preferred stock converted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$6M from sale of 1,000,967 shares at $6.00/share; $3.6M received by Apr 5, 2023.","Funds to accelerate clinical trial of Biostage Esophageal Implant (BEI) for esophageal cancer/injury.","All Series E Preferred Stock plus accrued dividends will convert to ~675,000 common shares at $6.00, eliminating Series E.","FDA approved 10-patient Phase 1/2 trial for BEI; potential expansion to pediatric and bronchial indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317769,"accession_number":"0001493152-23-007607","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Biostage appoints Jerry He as CEO, replacing David Green; sets compensation terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jerry He appointed Chairman and CEO effective March 1, 2023; David Green remains on board.","Base salary $300,000, rising to $500,000 if private placement raises ≥$4M.","Time-based option grant: 732,384 shares; milestone grant up to 488,256 shares.","If offering raises <$4M, annual option grant valued at $200,000 in lieu of additional cash.","Annual bonus up to 100% of base salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317768,"accession_number":"0001493152-23-006927","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["1.01","8.01","5.02","9.01"],"status":"ready","headline":"Biostage appoints Jerry He as Chairman and CEO; David Green remains on Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jerry He appointed Chairman and CEO effective March 1, 2023, replacing David Green.","David Green to remain on Board and support transition.","He previously served as EVP of Bright Scholar Education and CEO of Noah Education.","Biostage is a clinical-stage biotech developing regenerative medicine for esophageal cancer.","Company plans to begin FDA-approved clinical trial for esophageal cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317767,"accession_number":"0001493152-23-002582","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["3.02","5.02"],"status":"ready","headline":"Biostage CEO David Green reduces cash salary to $35,568; receives $264K stock option","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Green reduced annual base salary from $300,000 to $35,568 (minimum required by law).","Received nonqualified stock option valued at $264,432 (Black-Scholes) for the salary reduction difference.","Option vests monthly over 12 months; exercise price equals closing price on grant date (Jan 25, 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317766,"accession_number":"0001563665-23-000004","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Biostage CEO David Green made permanent; new agreement includes $300k salary, stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Interim tag removed; David Green named permanent CEO effective January 11, 2023.","Annual base salary set at $300,000; cash incentive up to 100% of base salary.","Initial stock option grants: $200k Black-Scholes value (monthly vesting over 12 months); fully vested option for $200k; LTI grant of 6% of outstanding shares (36-month vesting).","Severance: $300,000 cash plus $200k Black-Scholes option if terminated without cause or for good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336029,"accession_number":"0001563665-22-000023","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-12-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biostage selects IQVIA as CRO for FDA-approved esophageal implant trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IQVIA, a global CRO with GI and cell-therapy trial experience, to manage Biostage's first clinical trial.","Trial is FDA-approved open-label study for up to 10 patients requiring removal of up to 6cm esophagus (cancer, trauma, birth defects).","Primary endpoint: continuous biological conduit at 3 months; first human use met endpoint by 1 month (JTO CRR, Aug 2021).","Preliminary contract covers first stage; second comprehensive contract expected. Trial duration 4-6 years with staggered enrollment and 2-year follow-up.","CEO: current 5-year survival for esophageal cancer only 20%; >600k new cases annually worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336028,"accession_number":"0001563665-22-000019","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biostage Announces Publication Showing Rapid Esophageal Regeneration in Pigs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Publication in Journal of Immunology and Regenerative Medicine describes regeneration after Biostage Esophageal Implant in nine pigs with full circumferential replacement.","All animals regenerated a continuous biological conduit by 28 days; some as early as 14 days.","Regeneration time compares favorably with FDA-approved clinical trial primary endpoint of 90 days.","Biostage expects to initiate patient recruitment in first clinical trial in early 2023.","Study also quantified epithelialization and fate of adipose-derived mesenchymal stromal cells."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336027,"accession_number":"0001563665-22-000010","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biostage reports Q3 net loss of $1.1M ($0.10/share); cash runway into Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.1M for Q3 2022 vs $0.8M in Q3 2021; EPS -$0.10 vs -$0.08.","Operating cash $3.0M as of Sept 30, 2022; cash used in ops $3.4M in first 9 months.","Expects cash to fund operations into Q2 2023.","Received U.S. patent for cellularized patch-based scaffolds (Biostage Tissue Patch) on Oct 25, 2022.","Appointed Joseph Damasio as CFO on Aug 8, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336026,"accession_number":"0001558370-22-014954","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Biostage dismisses auditor Wei, Wei & Co. and engages Marcum LLP; prior FY2021 report had going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Wei, Wei & Co. as independent auditor on Oct 10, 2022.","FY2021 audit opinion included a going concern paragraph about substantial doubt.","No disagreements with Wei on accounting principles or practices during recent years.","Engaged Marcum LLP as new independent registered public accounting firm on Oct 10, 2022.","No prior consultations with Marcum on accounting or audit matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353432,"accession_number":"0001104659-22-101343","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K/A","filed_at":"2022-09-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biostage adopts annual say-on-pay votes after stockholder advisory vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Advisory vote: 7,539,731 shares favored one year, 28,038 three years, 110,760 abstained.","Board decided to hold future say-on-pay votes annually until next frequency vote (no later than 2028).","Amendment solely discloses frequency decision; no other changes to original 8-K from June 22, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353435,"accession_number":"0001104659-22-088054","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Biostage appoints Joseph Damasio as CFO; $250K salary, 116K-share option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Damasio appointed CFO effective August 8, 2022; brings capital raising and biotech finance experience.","Initial annual base salary of $250,000, plus $25,000 bonus for remainder of FY2022 subject to milestones.","Granted nonqualified stock option for 116,156 shares vesting equally over four years.","Company intends to relist on NASDAQ and start clinical trial for esophageal implant.","Interim CEO David Green highlights Damasio's skills for operational management and capital raises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353434,"accession_number":"0001558370-22-012218","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biostage reports Q2 2022 net loss of $1.3M; raises $5.1M in private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.3M ($0.12 per share) vs $0.4M loss in Q2 2021; increase due to higher legal costs and prior-year PPP loan forgiveness.","Completed private placement in May 2022, generating net proceeds of ~$5.1M to fund clinical development of Biostage Esophageal Implant (BEI).","Operating cash on-hand of $4.6M as of June 30, 2022; expected runway into Q2 2023.","Executed settlement with Harvard Bioscience and plaintiffs in wrongful death litigation; no admission of liability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353433,"accession_number":"0001558370-22-011661","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biostage shareholders approve reverse stock split ratio of 1-for-1.25 to 1-for-5","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to amend charter to effect reverse stock split approved with 7,072,052 votes for, 196,116 against, 742 abstained.","Board retains discretion to choose final ratio between 1:1.25 and 1:5 and to set timing within one year.","Special meeting held July 28, 2022; result filed August 2, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371165,"accession_number":"0001104659-22-073529","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biostage shareholders elect Chen and Sanchez as Class III directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jason Jing Chen elected with 7,668,383 votes for, 11,776 withheld.","Herman Sanchez elected with 7,670,505 votes for, 9,654 withheld.","Advisory vote on executive compensation approved: 7,561,012 for, 15,553 against.","Advisory vote on frequency of say-on-pay: 1-year interval selected (7,539,731 votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371164,"accession_number":"0001558370-22-009976","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["3.02","3.03","5.03","9.01"],"status":"ready","headline":"Biostage issues $4M Series E Convertible Preferred to Harvard Bioscience to satisfy indemnification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 4,000 shares of Series E Preferred at $1,000/share to HBIO on June 10, 2022, to settle $4M indemnification obligations.","8% annual dividend payable quarterly in additional Series E shares; ranks senior to common stock.","Mandatory conversion upon NASDAQ uplisting, IPO, or $4M+ private placement; optional conversion based on 60-day VWAP.","Consent rights restrict debt over $500K, certain related-party transactions, and issuance of senior or pari passu securities.","Beneficial ownership limitation capped at 9.99% on conversion; limited piggyback registration rights if Rule 144 unavailable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371163,"accession_number":"0001558370-22-008977","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biostage Q1 net loss widens to $2.2M; settles lawsuit, raises $5.1M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss of $2.2M ($0.20 per share) vs $0.9M loss ($0.09) in Q1 2021; G&A up $1.4M on legal costs.","Raised $5.1M via private placement on May 12, 2022 to fund clinical development of BEI.","Settled wrongful death lawsuit on April 27, 2022; total estimated costs $6.0M, $5.5M unpaid; HBIO to pay $4.0M.","Cash on hand $0.7M at March 31, 2022; after placement, cash expected to fund operations through Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371162,"accession_number":"0001104659-22-059902","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Biostage raises $5.1M in private placement to advance esophageal implant clinical trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$5.1M from new and existing investors via 854,771 shares and warrants for 427,390 shares at $5.92/unit.","Warrants exercisable at $8.88/share for 5 years; $4.8M received, $260K expected shortly.","Proceeds to accelerate FDA-approved 10-patient Phase 1/2 trial of Biostage Esophageal Implant for severe esophageal disease.","Company also developing Biostage Bronchial Implant for lung cancer and birth defects.","CEO David Green expressed optimism about advancing pipeline for patients and shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371161,"accession_number":"0001104659-22-052317","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Biostage settles wrongful death litigation; to issue $4M convertible preferred to HBIO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Biostage settles 2017 wrongful death suit; total costs estimated at ~$6M, $5.7M unpaid.","HBIO to pay $4M of costs; Biostage will issue $4M of 8% convertible preferred stock.","Preferred converts automatically upon qualified offering (e.g., NASDAQ uplisting or $4M+ private placement) at offering price.","Remaining ~$1.7M in costs and future legal expenses still payable by Biostage or indemnified to HBIO.","Neither party admits liability; claims dismissed with prejudice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371160,"accession_number":"0001558370-22-004990","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biostage FY2021 net loss widens to $8.0M on $3.3M litigation charge and higher legal costs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net loss of $5.9M ($0.55/share) vs $1.0M loss in Q4 2020; FY2021 loss $8.0M ($0.79/share).","Loss increase driven by $3.3M contingency charge for wrongful death litigation and $1.3M legal fees for insurance coverage.","Operating cash at Dec 31, 2021: $1.2M; management expects funding into early Q3 2022.","Proceeds of $2.8M from private placements (1,372,464 shares + warrants) helped offset $2.6M operating cash burn.","R&D costs decreased $0.5M in FY2021; notes payable forgiveness contributed $0.4M gain."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390134,"accession_number":"0001104659-22-011367","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biostage posts webinar video; interim CEO outlines plans for clinical trial, capital raise, NASDAQ uplisting","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Biostage posted video of January 27 webinars with founder/interim CEO David Green.","Webinar covered plans for approved clinical trial, raising capital, and uplisting to NASDAQ.","Video includes Q&A sessions from both webinars."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390133,"accession_number":"0001104659-22-008048","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2022-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biostage wins court order requiring insurer to pay legal defense; to host investor webinar Jan 27","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court ordered Medmarc to continue paying Biostage's legal defense in a wrongful death suit over a tracheal implant, finding Medmarc breached its duty and awarding attorneys' fees.","Biostage discontinued tracheal implant development and now focuses on esophageal implant, which has FDA approval for a clinical trial.","Interim CEO David Green will host webinars on Jan 27 to discuss the clinical trial, capital raising, and NASDAQ uplisting.","A second webinar is scheduled for Jan 27 at 8pm ET / Jan 28 9am Beijing time for investor Q&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408161,"accession_number":"0001104659-21-146581","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2021-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biostage highlights first-in-human esophageal success, FDA-approved IND, founder CEO return","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First-in-human esophageal implant at Mayo Clinic; paper published Aug 2021 concludes 'considerable clinical use'.","FDA-approved IND for Phase 1/2 trial (10 patients); two orphan-drug designations provide 7-year exclusivity.","Founder David Green returned as interim CEO and Chairman in Nov 2021; invested $250k in BSTG; compensation in options.","Cash ~$1.7M as of Nov 30, 2021; burn ~$250k/month; goals include raising capital, commencing trial, NASDAQ uplist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408160,"accession_number":"0001104659-21-144727","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2021-11-30T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Biostage appoints David Green as interim CEO; he invests $250,000 in private placement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Green appointed Interim CEO and Chairman; Jason Chen becomes Vice Chairman.","Green invests $250,000 for 72,464 shares and warrant for 36,232 shares at $3.45 (50% premium to Nov 26 close).","Green's salary set at Massachusetts minimum wage ($35,568) plus option grant of 374,094 shares (2/3 vest on milestones).","Green previously served as CEO and Chairman until 2015; returns to lead Biostage's esophageal implant development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408159,"accession_number":"0001104659-21-139180","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biostage reports Q3 net loss of $0.8M; cash $2.0M, funds ops into Q2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2021 was $0.8M ($0.8 per share) vs $0.7M ($0.07 per share) in Q3 2020.","Nine-month 2021 net loss of $2.1M ($0.22 per share) vs $3.8M ($0.45 per share) in prior comparable period.","Cash on-hand $2.0M as of Sep 30, 2021, up $1.5M from prior year.","Proceeds of $2.6M from private placements of 1.3M shares and warrants in first nine months of 2021.","Expects current cash to fund operating expenses and capex into Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427150,"accession_number":"0001104659-21-119084","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2021-09-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biostage loses product liability insurance coverage for wrongful death lawsuit; insurer files declaratory judgment","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On Sept 15, 2021, a product liability insurer denied coverage for the 2017 wrongful death suit and will stop defending after Sept 30, 2021.","Insurer filed a declaratory judgment complaint asking the court to rule no duty to defend, indemnify, or cover Biostage or Harvard Bioscience.","Company intends to vigorously defend the insurance coverage denial and the underlying case; previous sanctions were vacated on Aug 6, 2021.","If Biostage loses on merits and insurance does not cover, it may be forced to curtail or cease operations due to financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427149,"accession_number":"0001104659-21-113653","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2021-09-08T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Biostage raises $2.6M in private placements, appoints Jerry He to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $2.0M in Sept 2021 from DST Capital and An Zhang in private placement of 1M shares and warrants for 500K shares at $2.00 per unit.","Combined with $0.6M from earlier placements in May/June 2021, total cash infusion of $2.6M.","Proceeds expected to fund operations and capex into Q4 2021.","Appointed Jerry He (Executive Vice Chairman of Bright Scholar) as Class I independent director; options worth $25K + annual cash fees $20K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427148,"accession_number":"0001104659-21-105114","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2021-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biostage Q2 net loss narrows to $0.4M; cash $0.5M, funding into Q3 2021","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.4M ($0.04 per share) vs $1.2M loss in Q2 2020.","Improvement due to lower R&D, lower G&A, and $0.4M PPP loan forgiveness gain.","Cash on-hand of $0.5M as of June 30, 2021; expects to fund operations into Q3 2021.","No conference call held; company plans future call for clinical and business plans."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427147,"accession_number":"0001104659-21-090711","cik":1563665,"company_name":"Harvard Apparatus Regenerative Technology, Inc.","ticker":"HRGN","form_type":"8-K","filed_at":"2021-07-09T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Biostage replaces auditor RSM with Wei, Wei & Co. effective July 6, 2021","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RSM US LLP notified Biostage on May 25, 2021 that client-auditor relationship ceased.","Audit Committee engaged Wei, Wei & Co., LLP as new independent auditor on July 6, contingent on client acceptance.","No consultations with Wei on accounting principles or disagreements/reportable events occurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23030772.999999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}